VisionX Secures Tens of Millions in New Funding to Accelerate AI-Powered Digital Pathology
VCBeat (WeChat ID: vcbeat) has learned that Shenzhen Imsight Medical Technology Co., Ltd. (Imsight) recently announced the completion of a new round of financing amounting to tens of millions of yuan. This round was led by a renowned multinational industrial group, with existing investors Lenovo Capital and China Merchants Venture Capital continuing to inject capital.
Shenzhen Imsight Medical Technology Co., Ltd. is a technology-driven innovation company specializing in AI-powered medical imaging. At its core, the company leverages artificial intelligence, deep learning, and computer-aided medical image analysis technologies to develop high-quality medical image analysis software and large-scale imaging analysis platforms. By enabling intelligent recognition and analysis of big data in medical imaging, it rapidly and accurately provides auxiliary diagnostic and treatment recommendations, thereby enhancing the precision and efficiency of clinical diagnosis and therapy.
Since its inception, the company has been deeply engaged in the fields of pathology and radiology, dedicated to the R&D, product development, and commercialization of AI-assisted diagnostic products for medical imaging. The company boasts industry-leading, high-quality, large-scale structured data assets and internationally advanced algorithmic models, having won over 20 championships in international medical image recognition challenges. Its main products include an AI-assisted screening system for cervical liquid-based cytology, a chest CT imaging-assisted diagnostic system (comprising three intelligent modules for pulmonary nodules, rib fractures, and pneumonia), and a comprehensive chest DR screening system covering 19 common conditions such as pneumonia, tuberculosis, nodules, and emphysema. The variety, functionality, and performance of its products are all at the forefront of the industry.
The successful completion of this funding round demonstrates the capital market's recognition of Imsight's technological strength and commercialization capabilities.
The proceeds from this round of financing will be used to continue expanding R&D investment, while accelerating the establishment of a nationwide sales and service network to position the company for the Chinese market.Shenzhen Imsight Medical Technology Co., Ltd. Financing Event:
In July 2017, Imsight Technology completed a near-Pre-A round of financing, with Legend Capital as the investor;
In March 2018, Imsight Technology completed its Series A financing round, led by Shenzhen Capital Group.
In June 2018, Imsight Technology completed an additional round of Series A financing, with China Merchants Venture Capital as the investor.
Pathological diagnosis plays a crucial role in the clinical diagnostic process for diseases. However, it has long faced challenges such as high technical complexity and a shortage of pathologists, highlighting the significant development potential and practical value of artificial intelligence (AI) in this field. Taking liquid-based cytology for cervical cancer screening as an example, cervical cancer is the most common gynecological malignancy. The widespread application of cervical cytology screening enables early detection and treatment of cervical cancer and precancerous lesions, effectively helping to reduce incidence and mortality rates.
In 2009, the Chinese government launched a policy providing free screening for rural women, with the goal of achieving an 80% screening coverage rate by 2022. To achieve this target, screening institutions, already operating beyond capacity, faced even greater work pressure. Consequently, the National Health Commission proposed “leveraging artificial intelligence to facilitate large-scale cancer screening.” Imsight Technology has developed a comprehensive large-scale pathology diagnostic platform that integrates digital whole-slide image scanning, transmission, storage, annotation, and diagnosis. Covering multiple areas including histopathology and cytopathology, the platform effectively supports the diagnostic and research needs of medical institutions.
Among these, the liquid-based cervical cytology assisted screening system fully covers the automated screening of all 15 TBS lesion categories as defined by international guidelines. Equipped with a high-throughput scanner, it can automatically process over 2,000 cases per day, with both sensitivity and specificity exceeding 90%. Featuring rapid speed, high accuracy, and comprehensive functionality, the system effectively handles the initial screening of liquid-based cervical cytology, thereby supporting the achievement of cervical cancer screening goals.
Furthermore, the Imsight Pathology Large-Scale Diagnostic Platform also covers diseases such as bladder cancer, breast cancer, and renal cancer. Among these, the Guangdong Provincial Key Project in Next-Generation Artificial Intelligence—the “AI-Integrated Precision Diagnostic Platform for Bladder Cancer,” developed through a deep collaboration between Imsight Technology and Sun Yat-sen Memorial Hospital of Sun Yat-sen University—leverages non-invasive screening of exfoliated cells in urine combined with artificial intelligence technology to facilitate large-scale screening for bladder cancer.
Imsight Medical’s pathology products have made frequent appearances at prestigious industry events, including the China International Medical Equipment Fair (CMEF), conferences organized by the Chinese Association for the Promotion of Healthcare, the Annual Conference of Pathology of the Chinese Medical Association, and the National Conference on Medical Equipment, garnering widespread attention and recognition from experts and peers in the field.
In the coming years, Imsight will continue to prioritize its strategic layout in the smart pathology ecosystem. With AI applications at its core, the company will integrate upstream with tissue processing, staining, and digital pathology slide scanning manufacturers, while partnering downstream with hospitals and third-party pathology and clinical laboratories. By providing comprehensive end-to-end smart pathology solutions, Imsight aims to advance pathological diagnosis toward greater intelligence.
Over the past few years, AI-assisted products in radiology have seen continuous technological and product maturation, with hospital radiology departments demonstrating steadily increasing acceptance of AI. Certain products, such as those for AI-assisted diagnosis of pulmonary nodules on CT scans, have gained widespread recognition among physicians, and their clinical and commercial value has been progressively validated.
Since 2017, Shenzhen Imsight Medical Technology Co., Ltd. has been developing AI-powered medical imaging products. To date, the company has launched two major product platforms: an AI-assisted diagnostic system for chest CT scans (featuring three intelligent modules for pulmonary nodules, rib fractures, and pneumonia) and a comprehensive AI-assisted screening system for chest digital radiography (DR), which covers 19 common conditions including pneumonia, tuberculosis, pulmonary nodules, and emphysema. These platforms lead the industry in terms of disease coverage, functionality, and performance. The related products have been clinically deployed in over one hundred hospitals and medical institutions both domestically and internationally, serving tens of thousands of patients daily.
Early this year, an unprecedented global outbreak of the novel coronavirus occurred. In response to the need for COVID-19 screening, Imsight Technology rapidly launched an intelligent screening solution combining CT and DR imaging. This product demonstrates high sensitivity in detecting early-stage pneumonia, enabling comprehensive analysis of lesion characteristics—including localization, segmentation, distribution, and associations—along with full longitudinal follow-up tracking. The solution has been deployed in hospitals across multiple regions, including Shenzhen, Guangzhou, Xiamen, Chengdu, and Shandong Province, with a cumulative daily processing capacity of up to 3,000 cases, effectively supporting epidemic control efforts.
To further deepen hospitals’ understanding of AI products and enable more radiologists to experience them firsthand, Imsight has offered doctors free access to “AI-Powered Radiology Diagnostic Platform Imsight Radiology Platform™“Trial service, this isChina's First Free-to-Try Medical Imaging AI Platform, with the aim of strengthening interactions between physicians and AI through this event, deepening hospitals’ and physicians’ understanding of AI products, and enabling more hospitals and physicians to gain hands-on experience with and adopt AI imaging solutions.
Currently,Imsight’s Radiology Products Have Obtained NMPA Class II Certification, lung CT and cervical pathology diagnostics have been submitted for NMPA Class III certification.In addition to the domestic NMPA, Imsight Technology is also actively preparing for certification in the EU CE and US FDA registration application stages.